Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Diana J. Moke"'
Autor:
Erin M. Mobley, Diana J. Moke, Joel Milam, Carol Y. Ochoa‐Dominguez, Julia Stal, Halle Mitchell, Naghmeh Aminzadeh, Maria Bolshakova, Raymond B. Mailhot Vega, Jennifer Dinalo, Aneesa Motala, Susanne Hempel
Publikováno v:
Cancer Medicine, Vol 12, Iss 17, Pp 18281-18305 (2023)
Abstract Background Childhood cancer survivors (CCS) experience many long‐term health problems that can be mitigated with recommended survivorship care. However, many CCS do not have access to survivorship care nor receive recommended survivorship
Externí odkaz:
https://doaj.org/article/31cf169957474c95a362f5dc67f2d6fc
Autor:
Murad Alturkustani, Leo Mascarenhas, Diana J. Moke, Linda J Szymanski, Gordana Raca, Rachel Gallant, Roshan Mahabir, Sarangarajan Ranganathan, Jaclyn A. Biegel
Publikováno v:
International Journal of Surgical Pathology. 30:307-312
The small cell undifferentiated component of hepatoblastoma is an uncommon histologic component and is distinguished from small cell undifferentiated like pattern (originally called hepatoblastoma and now recognized to be malignant rhabdoid tumor) by
Autor:
Crystal Bockoven, Joseph M Miller, Sally Cohen-Cutler, Minnelly Luu, Dean M. Anselmo, Diana J. Moke, Jessica L. Lee, Linda J Szymanski
Publikováno v:
Pediatric Dermatology. 38:1276-1282
We present a complex case of a neonate, delivered urgently for hydrops fetalis, with a large vascular mass of the extremity, diagnosed postnatally as a congenital hemangioma. The patient suffered immediate cardiac compromise and severe coagulopathy a
Publikováno v:
Cancers
Cancers; Volume 13; Issue 16; Pages: 3956
Cancers, Vol 13, Iss 3956, p 3956 (2021)
Cancers; Volume 13; Issue 16; Pages: 3956
Cancers, Vol 13, Iss 3956, p 3956 (2021)
Simple Summary Cancer survivors are at risk for developing serious health problems and dying prematurely. Adolescents and young adults (AYAs, aged 15–39 years at diagnosis) are a unique population challenged with different cancer types and treatmen
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 28:1612-1620
Background: Obesity is a known modifiable risk factor associated with adverse outcomes in children with cancer. We sought to determine whether obesity during childhood cancer treatment increases risk for second malignant neoplasms (SMN). Methods: In
Autor:
Erin M. Mobley, Susanne Hempel, Drizelle Baluyot, Diana J. Moke, Nosa Osazuwa, Jennifer E. Dinalo, Jai Kemp, Aneesa Motala, Maria Bolshakova, Joel Milam, Julia Stal, Carol Y. Ochoa
Objectives. Survival rates for pediatric cancer have dramatically increased since the 1970s, and the population of childhood cancer survivors (CCS) exceeds 500,000 in the United States. Cancer during childhood and related treatments lead to long-term
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a9b8451e126e4efe1cf246e253bacbf
https://doi.org/10.23970/ahrqepctb39
https://doi.org/10.23970/ahrqepctb39
Autor:
Wendy G. Mitchell, Larry Wang, Jaclyn A. Biegel, Jennifer A. Cotter, Michele VanHirtum-Das, Stefanie M. Thomas, Catherine Quindipan, Matthew Hiemenz, Fariba Navid, Sulagna C. Saitta, Diana J. Moke, Jianling Ji
Publikováno v:
Pediatric neurology. 114
Background Disorders in the PIK3CA-related overgrowth spectrum because of somatic mosaicism are associated with segmental overgrowth of the body in conjunction with vascular, skeletal, and brain malformations such as hemimegalencephaly. A pathogenic
Autor:
Dennis Deapen, Lihua Liu, Myles Cockburn, Ann S. Hamilton, Amie E. Hwang, Kai-Ya Tsai, David R. Freyer, Diana J. Moke, Juanjuan Zhang
Publikováno v:
JNCI: Journal of the National Cancer Institute. 111:509-518
Background Cancer survival among adolescents and young adults (AYAs) was previously reported as showing little or no improvement compared to younger or older counterparts. The role of the HIV/AIDS epidemic in the AYA survival deficit has not been eva
Autor:
Diana J. Moke, Stefanie M. Thomas, Matthew C. Hiemenz, Nick Shillingford, Ali Nael, Kasper S. Wang, Leo Mascarenhas, Jaclyn A. Biegel
Publikováno v:
Eur J Cancer
Publikováno v:
Journal of the Endocrine Society
Background: Pediatric bone diseases due to osteoclast overactivity have limited therapeutic options. Denosumab, a human monoclonal antibody against RANK-ligand, has been used in the treatment of these conditions despite limited pediatric safety data.